Ranganath Muniyappa1, Brent S Abel2, Asha Asthana2, Mary F Walter3, Elaine K Cochran2, Alan T Remaley4, Monica C Skarulis2, Phillip Gorden2, Rebecca J Brown2. 1. Diabetes, Endocrinology, and Obesity Branch, NIDDK, NIH, Bethesda, MD, USA. Electronic address: muniyapr@mail.nih.gov. 2. Diabetes, Endocrinology, and Obesity Branch, NIDDK, NIH, Bethesda, MD, USA. 3. Clinical Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 4. Lipoprotein Metabolism Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract
BACKGROUND: Reduced triglyceride clearance due to impaired lipoprotein lipase-mediated lipolysis contributes to severe hypertriglyceridemia in lipodystrophy. Angiopoietin-like protein 3 (ANGPTL3) and 4 (ANGPTL4) impair clearance of triglycerides by inhibiting lipoprotein lipase. Whether circulating ANGPTL3/4 levels are altered in lipodystrophy and the effects of leptin replacement on these ANGPTLs are unknown. OBJECTIVE: To examine if ANGPTL3/4 levels are elevated in patients with generalized lipodystrophy and assess the effects of leptin replacement on these ANGPTLs. METHODS: Preleptin treatment plasma levels of ANGPTLs in patients with generalized lipodystrophy (n = 22) were compared with healthy controls (n = 39) using a post hoc case-control study design. In a prospective open-label study, we studied the effects of metreleptin therapy (16-32 weeks) on plasma ANGPTL3/4 in patients with generalized lipodystrophy. RESULTS: Plasma ANGPTL3 (geometric mean [95% confidence interval]; 223 [182-275] vs 174 ng/mL [160-189], P = .02) but not ANGPTL4 levels (55 [37-81] vs 44 ng/mL [37-52], P = .26) were higher in patients with lipodystrophy compared with healthy controls. There was a significant decrease in total cholesterol, triglycerides, and glycosylated hemoglobin (A1C) levels following metreleptin therapy. After metreleptin, ANGPTL3 concentrations decreased significantly (223 [182-275] vs 175 ng/mL [144-214], P = .01) with no change in ANGPTL4 (55 [37-81] vs 48 ng/mL [32-73], P = .11). CONCLUSIONS: These findings suggest that elevated plasma levels of ANGPTL3 in leptin-deficient states is attenuated with leptin therapy. Published by Elsevier Inc.
BACKGROUND: Reduced triglyceride clearance due to impaired lipoprotein lipase-mediated lipolysis contributes to severe hypertriglyceridemia in lipodystrophy. Angiopoietin-like protein 3 (ANGPTL3) and 4 (ANGPTL4) impair clearance of triglycerides by inhibiting lipoprotein lipase. Whether circulating ANGPTL3/4 levels are altered in lipodystrophy and the effects of leptin replacement on these ANGPTLs are unknown. OBJECTIVE: To examine if ANGPTL3/4 levels are elevated in patients with generalized lipodystrophy and assess the effects of leptin replacement on these ANGPTLs. METHODS: Preleptin treatment plasma levels of ANGPTLs in patients with generalized lipodystrophy (n = 22) were compared with healthy controls (n = 39) using a post hoc case-control study design. In a prospective open-label study, we studied the effects of metreleptin therapy (16-32 weeks) on plasma ANGPTL3/4 in patients with generalized lipodystrophy. RESULTS: Plasma ANGPTL3 (geometric mean [95% confidence interval]; 223 [182-275] vs 174 ng/mL [160-189], P = .02) but not ANGPTL4 levels (55 [37-81] vs 44 ng/mL [37-52], P = .26) were higher in patients with lipodystrophy compared with healthy controls. There was a significant decrease in total cholesterol, triglycerides, and glycosylated hemoglobin (A1C) levels following metreleptin therapy. After metreleptin, ANGPTL3 concentrations decreased significantly (223 [182-275] vs 175 ng/mL [144-214], P = .01) with no change in ANGPTL4 (55 [37-81] vs 48 ng/mL [32-73], P = .11). CONCLUSIONS: These findings suggest that elevated plasma levels of ANGPTL3 in leptin-deficient states is attenuated with leptin therapy. Published by Elsevier Inc.
Entities:
Keywords:
Angiopoietin-like protein 3; Leptin; Lipodystrophy
Authors: Bernardo L Wajchenberg; Rosângela F Amâncio; Ana T Santomauro; Raul C Maranhão Journal: Clin Endocrinol (Oxf) Date: 2004-09 Impact factor: 3.478
Authors: Marissa Lightbourne; Anna Wolska; Brent S Abel; Kristina I Rother; Mary Walter; Yevgeniya Kushchayeva; Sungyoung Auh; Robert D Shamburek; Alan T Remaley; Ranganath Muniyappa; Rebecca J Brown Journal: J Endocr Soc Date: 2020-12-04
Authors: Camilla O D Araújo; Renan M Montenegro; Amanda P Pedroso; Virgínia O Fernandes; Ana Paula D R Montenegro; Annelise B de Carvalho; Lila M Oyama; Carla S C Maia; Eliane B Ribeiro Journal: PLoS One Date: 2021-01-07 Impact factor: 3.240
Authors: Maria C Foss-Freitas; Baris Akinci; Adam Neidert; Victoria J Bartlett; Eunju Hurh; Ewa Karwatowska-Prokopczuk; Elif A Oral Journal: Lipids Health Dis Date: 2021-12-05 Impact factor: 3.876
Authors: Elif A Oral; Phillip Gorden; Elaine Cochran; David Araújo-Vilar; David B Savage; Alison Long; Gregory Fine; Taylor Salinardi; Rebecca J Brown Journal: Endocrine Date: 2019-02-25 Impact factor: 3.633